^
    KDR C482R
    Clear Cell Renal Cell Carcinoma
    crizotinib + pazopanib
    Sensitive
    :
    C3
    Onco Targets Ther - 3d
    No biomarker
    RCC
    pembrolizumab + lenvatinib
    Sensitive
    :
    B
    Merck (MSD) Press Release - 4d
    No biomarker
    RCC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 2wk
    No biomarker
    RCC
    nivolumab + cabozantinib tablet
    Sensitive
    :
    A1
    PD-L1 expression
    RCC
    avelumab + axitinib
    Sensitive
    :
    A1
    No biomarker
    RCC
    avelumab + axitinib
    Sensitive
    :
    A1
    No biomarker
    RCC
    Mvasi (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    RCC
    Zirabev (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    RCC
    sorafenib
    Sensitive
    :
    A1
    No biomarker
    RCC
    tivozanib
    Sensitive
    :
    A1
    No biomarker
    RCC
    temsirolimus
    Sensitive
    :
    A1
    No biomarker
    RCC
    sunitinib
    Sensitive
    :
    A1
    No biomarker
    RCC
    everolimus + lenvatinib
    Sensitive
    :
    A1
    No biomarker
    RCC
    everolimus
    Sensitive
    :
    A1
    No biomarker
    RCC
    bevacizumab + pegylated interferon α -2a
    Sensitive
    :
    A1
    No biomarker
    RCC
    cabozantinib tablet
    Sensitive
    :
    A1
    No biomarker
    RCC
    pembrolizumab + axitinib
    Sensitive
    :
    A1
    No biomarker
    RCC
    nivolumab
    Sensitive
    :
    A1
    No biomarker
    RCC
    Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
    Sensitive
    :
    A1
    No biomarker
    RCC
    Aybintio (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    RCC
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    No biomarker
    RCC
    axitinib
    Sensitive
    :
    A1
    No biomarker
    RCC
    pazopanib
    Sensitive
    :
    A1
    No biomarker
    RCC
    aldesleukin
    Sensitive
    :
    A1
    No biomarker
    RCC
    Bevax (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    RCC
    bevacizumab
    Sensitive
    :
    A2
    No biomarker
    Clear Cell Renal Cell Carcinoma
    bevacizumab + pegylated interferon α -2a
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES